Imago BioSciences Files up to $100M IPO

Imago BioSciences (NASDAQ: IMGO) files for up to $100M IPO.

IMGO is a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. They are focused on improving the quality of life of patients with cancer and bone marrow diseases in addition to prolonging their lives

Jefferies, Cowen, Stifel and Guggenheim Securities will serve as underwriters.

You May Also Be Interested In